Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease:...

por Driessen, M. T., Whalen, J., Seewoodharry Buguth, B., Vallejo-Aparicio, L. A., Naya, I. P., Asukai, Y., Alcázar-Navarrete, B., Miravitlles, M., García-Río, F., Risebrough, N. A.
Publicado 2018

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulm...

por Driessen, M. T., Whalen, J., Buguth, B. Seewoodharry, Vallejo-Aparicio, L. A., Naya, I. P., Asukai, Y., Alcázar-Navarrete, B., Miravitlles, M., García-Río, F., Risebrough, N. A.
Publicado 2019

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

por Mellado, B, Font, A, Alcaraz, A, Aparicio, L A, Veiga, F J G, Areal, J, Gallardo, E, Hannaoui, N, Lorenzo, J R M, Sousa, A, Fernandez, P L, Gascon, P
Publicado 2009